Dezocine inhibits cell proliferation, migration, and invasion by targeting CRABP2 in ovarian cancer

Zhang, Chuanfeng; Pan, Ruirui; Ma, Shuangshuang; Xu, Shoucai; Wang, Baosheng

doi:10.1515/med-2022-0541

Cited by 4 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, the anti-tumor effects of Dizocine have already been demonstrated. Dezocine inhibited ovarian cancer cell viability [9]. Dezocine also inhibited the migration as well as the invasion of ovarian cancer cells [9].…”

Section: Discussionmentioning

confidence: 97%

“…Sevoflurane has been shown to have antitumor effects in different cancers, such as ovarian cancer [8]. Dezocine has also been widely used in clinical anesthesia and analgesia after cancer surgery without side effects [9]. Desocine inhibited ovarian cancer cell viability [9].…”

Section: Introductionmentioning

confidence: 99%

“…Dezocine has also been widely used in clinical anesthesia and analgesia after cancer surgery without side effects [9]. Desocine inhibited ovarian cancer cell viability [9]. Dezocine inhibits the motility of ovarian cancer cells and promotes cell apoptosis [9].…”

Section: Introductionmentioning

confidence: 99%

“…Desocine inhibited ovarian cancer cell viability [9]. Dezocine inhibits the motility of ovarian cancer cells and promotes cell apoptosis [9]. In addition, the Akt/mTOR pathway is also restrained by Dezocine [9].…”

Section: Introductionmentioning

confidence: 99%

“…Dezocine inhibits the motility of ovarian cancer cells and promotes cell apoptosis [9]. In addition, the Akt/mTOR pathway is also restrained by Dezocine [9]. Dizocine induces apoptosis of HeLa cells through affecting endoplasmic reticulum stress [10].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Dezocine inhibits proliferation as well as migration of endometrial carcinoma in vitro

2023

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

Endometrial cancer (EC) includes several epithelial malignancies existed in the endometrium tissues. To improve the prognosis of EC, it is greatly needed to find new drugs. Dezocine, a organic compound, is an κ agonist and a µ receptor antagonist, is used in clinical anesthesia after cancer surgery with few side effects, and its anti-tumor effects have also been demonstrated in several tumors. However, the effects of Dezocine on EC progression have not been elusidated. Herein, we investigated the role of Dezocine in EC cell functions. Through a series of cellular assays, such as cell counting kit-8 (CCK-8), flow cytometry (FCM), transwell assays, we found that Dezocine suppressed the EC cell proliferation, and stimulated EC cell apoptosis in vitro. Furthermore, results revealed Dezocine restrained the motility, including migration and invasion of EC cells. Mechanically, Dezocine suppressed the Akt (protein kinase B, PKB)/mammalian target of rapamycin (mTOR) pathway in EC cells, thereby suppressing EC cell proliferation as well as migration in vitro. In conclusion, Dezocine inhibits proliferation as well as migration of EC in vitro.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Dezocine inhibits proliferation as well as migration of endometrial carcinoma in vitro

2023

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

show abstract

Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability

Barr,

Schmidt,

Thakrar

et al. 2024

CNS Neurosci Ther

View full text Add to dashboard Cite

AimsOpioid use disorder (OUD) remains a serious public health problem. Opioid maintenance treatment is effective but under‐utilized, hard to access under existing federal regulations, and, once patients achieve OUD stability, challenging to discontinue. Fewer than 2% of persons with OUD stop using opioids completely. There have been calls from public advocacy groups, governmental agencies, and public health officials for new treatments for OUD. Dezocine, a non‐scheduled opioid previously used in the United States and currently widely prescribed in China for pain management, could be a candidate for a novel OUD treatment medication in the U.S. Nonetheless, to date, there have been no reviews of the clinical and preclinical literature detailing dezocine's abuse potential, a key consideration in assessing its clinical utility.DiscussionThere are no English language reports of human abuse, dependence, or overdose of dezocine, despite years of extensive clinical use. There are a few case reports of dezocine abuse in the Chinese literature, but there are no reports of overdose deaths. Dezocine is perceived as an opioid and is “liked” by opioid‐experienced human and non‐human primates, properties that are not dose‐dependent and are mitigated by ceiling effects—higher doses do not result in more “liking.” There is little withdrawal, spontaneous or precipitated, in humans, monkeys, rats, or mice treated chronically with dezocine alone. However, at some doses, dezocine can precipitate withdrawal in humans and monkeys dependent on other opioids. In rodents, dezocine reduces the severity of morphine withdrawal and the rewarding properties of other opioids.ConclusionsAlthough dezocine is reinforcing in humans and monkeys with prior or concurrent opioid use within a restricted dose range, there are only a few anecdotal reports of dezocine abuse despite of the long history of use in humans. Given the evidence of dezocine's limited abuse potential, it could be useful both as a treatment for OUD. However, in‐depth studies would be required for dezocine to be re‐considered for clinical use.

show abstract

Exploring the cellular and molecular differences between ovarian clear cell carcinoma and high-grade serous carcinoma using single-cell RNA sequencing and GEO gene expression signatures

Guo,

Zhang,

Gao

et al. 2023

Cell Biosci

View full text Add to dashboard Cite

The two most prevalent subtypes of epithelial ovarian carcinoma (EOC) are ovarian clear cell carcinoma (OCCC) and high-grade serous ovarian carcinoma (HGSC). Patients with OCCC have a poor prognosis than those with HGSC due to chemoresistance, implying the need for novel treatment target. In this study, we applied single-cell RNA sequencing (scRNA-seq) together with bulk RNA-seq data from the GEO (Gene Expression Omnibus) database (the GSE189553 dataset) to characterize and compare tumor heterogeneity and cell-level evolution between OCCC and HGSC samples. To begin, we found that the smaller proportion of an epithelial OCCC cell subset in the G2/M phase might explain OCCC chemoresistance. Second, we identified a possible pathogenic OCCC epithelial cell subcluster that overexpresses LEFTY1. Third, novel biomarkers separating OCCC from HGSC were discovered and subsequently validated on a wide scale using immunohistochemistry. Amine oxidase copper containing 1 (AOC1) was preferentially expressed in OCCC over HGSC, while S100 calcium-binding protein A2 (S100A2) was detected less frequently in OCCC than in HGSC. In addition, we discovered that metabolic pathways were enriched in the epithelial compartment of the OCCC samples. In vitro experiments verified that inhibition of oxidative phosphorylation or glycolysis pathways exerted direct antitumor effects on both OCCC and HGSC cells, while targeting glutamine metabolism or ferroptosis greatly attenuated chemosensitivity only in OCCC cells. Finally, to determine whether there were any variations in immune cell subsets between OCCC and HGSC, data from scRNA-seq and mass cytometry were pooled for analysis. In summary, our work provides the first holistic insights into the cellular and molecular distinctions between OCCC and HGSC and is a valuable source for discovering new targets to leverage in clinical treatments to improve the poor prognosis of patients with OCCC.

show abstract

Dezocine inhibits cell proliferation, migration, and invasion by targeting CRABP2 in ovarian cancer

Cited by 4 publications

References 36 publications

Dezocine inhibits proliferation as well as migration of endometrial carcinoma in vitro

Dezocine inhibits proliferation as well as migration of endometrial carcinoma in vitro

Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability

Exploring the cellular and molecular differences between ovarian clear cell carcinoma and high-grade serous carcinoma using single-cell RNA sequencing and GEO gene expression signatures

Contact Info

Product

Resources

About